Edgewise Therapeutics (EWTX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of three directors to serve until the 2029 Annual Meeting: Laura Brege, Badreddin Edris, Ph.D., and Jonathan Root, M.D.
Ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Advisory vote on the compensation of named executive officers.
Proxies may vote on other business that may properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Annual meeting scheduled for June 4, 2026, at company headquarters in Boulder, Colorado.
Executive compensation and say-on-pay
Advisory vote to approve the compensation of named executive officers is included as a voting item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Edgewise Therapeutics
- Proxy covers director elections, auditor ratification, and executive pay, with strong governance focus.EWTX
Proxy filing23 Apr 2026 - 7500 advances toward Phase III in HCM, with Becker data showing disease stabilization.EWTX
Leerink Global Healthcare Conference 202611 Mar 2026 - Pivotal trial data expected in 2026–2027; Q4 net loss rose to $50.2M, cash at $530.1M.EWTX
Q4 202526 Feb 2026 - Phase III readouts and new cardiac programs drive momentum, with strong commercial readiness.EWTX
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - EDG-7500 reduced LVOT gradients and NT-proBNP in HCM without lowering LVEF.EWTX
Study Update20 Jan 2026 - Pivotal data and strong financials drive late-stage muscle and cardiac disease programs.EWTX
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Sevasemten reduced muscle damage biomarkers and stabilized function in Becker phase 2 trial.EWTX
Status Update12 Jan 2026 - Sevasemten reduced muscle damage biomarkers and stabilized function in Becker muscular dystrophy.EWTX
Study Update12 Jan 2026 - Advancing novel therapies for muscle diseases with strong clinical progress and financial strength.EWTX
Corporate Presentation12 Jan 2026